DAIC Editor Dave Fornell shares his choices for the most innovative new technologies in nuclear imaging that were on display at the 2014 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.
VIDEO: Early Discontinuation of DAPT in High Bleeding Risk Patients With the Synergy Stent
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the cardiac catheterization laboratories at NewYork-Presbyterian (NYP) Hospital, shares the findings of the late-breaking EVOLVE Short DAPT study presented as a late-breaking trial at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting. It evaluated the safety of early dual antiplatelet therapy (DAPT) discontinuation in patients with high bleeding risk treated with the a Boston Scientific Synergy bioabsorbable polymer coated drug-eluting stent (DES).
With the advancement of new DES technologies using thinner struts and new types of drug-carrier polymer techniques, the risk of late-stent thrombosis has been greatly reduced, meaning there is less need for long-term DAPT. For patients who are at high risk for bleeding, who have ulcers or other types of gastrointestinal (GI) bleeding, or those going into surgery, it would be beneficial to reduce the time period for DAPT, and several late-breaking trials examined this at TCT 2019.
Here are the other late-breaking DAPT studies:
Learn how Lumedx can help hospitals reduce heart failure re-admissions and improve patient care with HealthView Heart Failure. The innovative solution integrates inpatient and home-health patient data.
Satoshi Minoshima, M.D., Ph.D., chairman of the Society of Nuclear Medicine and Molecular Imaging Scientific Committee, discusses the new technologies and trends at SNMMI 2014.
McKesson is introducing the future of enterprise medical imaging and guiding thousands of healthcare enterprises like yours to the forefront of the ever-evolving healthcare landscape. With input from industry experts and an involved user community we have packed the new release of the McKesson Cardiology CVIS with enhancements you can use to help improve quality of care, boost efficiencies and reduce costs while helping to increase physician and staff satisfaction. For more information: www.mckesson.com/cardiology This video is sponsored by McKesson
DAIC Editor Dave Fornell offers his choices of the most innovative new cardiovascular technologies shown on the expo floor at the American College of Cardiology (ACC) 2014 meeting.
Bioresorbable stent technology was one of the big interventional technologies discussed at the American College of Cardiology (ACC) 2014 meeting. Doug Drachman, M.D., Mass General Hospital, explains where the technology is today and what we will likely see in the future. Read the article "FDA Approves First Totally Bioresorbable Stent."
The biggest late-breaking news to come out of the American College of Cardiology (ACC) 2014 meeting was from the CoreValve High-Risk pivotal trial, which showed a transcatheter valve offers a 26 percent survival benefit over surgical valve replacement. Co-Principal Investigator David Adams, M.D., explained the impact of the trial.
A major disappointment earlier this year was the announcement by Medtronic that its renal denervation system failed to meet its primary endpoint for efficacy in the U.S. SYMPLICITY HTN-3 trial. Michael Jaff , D.O., worked as part of the core lab for the trial and explains the trial outcomes and the future of renal denervation technology. He spoke to DAIC at the 2014 American College of Cardiology (ACC) meeting where the trial results were released.
Related Renal Denervation Content:
GE Healthcare is dedicated to helping healthcare organizations build a roadmap for a comprehensive radiation dose management strategy. Learn about current trends in dose management and how GE Healthcare's DoseWatch solution can help you. Read the article "The Role of Dose Tracking Systems in Radiation Safety Programs."
A big trend in healthcare IT at HIMSS 2014 was the creation of enterprise-wide image access systems. With the introduction of vendor neutral archives (VNAs), enterprise imaging will increasingly be taken out of the hands of radiology and move to the responsibility of hospital IT directors. In this form, radiology may become just another department contributing images to the VNA. HIMSS also highlighted the proliferation of new, inexpensive home use patient monitors.
The Miron Cardiac Care Center at Crouse Hospital in Syracuse, N.Y., deployed Lumdex's HealthView system for anywhere, anytime physician reporting, consolidated cardiology data, and improved efficiency.
Hear why Siemens SOMATOM Definition Edge is the CT your emergency department (ED) has been dreaming about from the leadership at Gwinett Medical Center. From physicians to the C-suite, see why the Edge is helping them meet their most demanding and time sensitive imaging needs with low-dose and high image quality.
DAIC Editor Dave Fornell offers his choices of the most innovative new cardiovascular technologies discussed in sessions and shown on the expo floor at the Transcatheter Cardiovascular Therapeutics (TCT) 2013 meeting.
Scott Lim, M.D., director of the Heart Valve Center at the University of Virginia Medical Center, investigator in the EVEREST and COAPT trials, discusses the MitraClip transcatheter mitral valve repair system at TCT 2013. The device recieved FDA clearance a couple days before TCT.
Herbert Aronow, M.D., MPH, St. Joseph Mercy Hospital, Ann Arbor, and an active member of ACC and SCAI, explains the top interventional cardiology highlights at TCT 2013.
This animation, provided by Abbott Vascular, demonstrates how the U.S. Food and Drug Administration (FDA)-cleared MitraClip transcatherer mitral valve repair system is implanted in the heart
The MitraClip was originally designed for high-risk surgical patients, who often will not be operated on by cardiac surgeons because of the mortality risk. These patients might be eligible for this less-invasive treatment option. The MitraClip device used in this transcatheter mitral valve repair (TMVR) procedure only involves a small puncture in the femoral vein, rather than open-heart surgery and the need to stop the heart.
The delivery catheter is pushed up into the heart and a transseptal puncture is made in the atrial wall. The catheter is then advanced from the right into the left atrium. It is bent 90 degrees to access the mitral valve and to attach the clip to the native valve leaflets.
The procedure it performed under transesophageal echocardiography (TEE) in a cath lab. The ultrasound imaging allows real-time assessment of device and valve leaflet positioning and shows when the leaflets are fully engaged by the device for final deployment. In addition, 3-D Doppler ultrasound is used to show blood flow. This is used to identify the location of the regurgitant jet and any residual jet after the device is implanted. To resolve any addition MR seen in the TEE might require the placement of additional clips.
Related Transcatheter Mitral Valve Technology Content:
VIDEO: Update of Mitral Valve Repair and Replacement Technologies - Interview with Ted Feldman, M.D.
VIDEO: Evolution of Transcatheter Mitral Valve Repair at the University of Colorado — Interview with John Carroll, M.D., and Robert Quaife, M.D.
VIDEO: MitraClip to Treat Heart Failure - Results of the COAPT Trial — Interview with William Abraham M.D.
VIDEO: Impact of the COAPT Trial on Heart Failure Patients With Functional Mitral Regurgitation — Interview with Andreas Brieke, M.D.
VIDEO: Echocardiographic Findings in the COAPT Trial — Interview with Federico Asch, M.D.
VIDEO: Transcatheter Mitral Valve Interventions at Henry Ford Hospital — Interview with Marvin Eng, M.D., and William O'Neill, M.D.
VIDEO: Transcatheter Mitral Valve Implantation in Practice and Technologies in Development - Interview with Adam Greenbaum, M.D.
VIDEO: Overview of Transcatheter Mitral Valve Repair Technologies — Interview with Ted Feldman, M.D.
VIDEO: The Cardiac Surgeon Perspective on Transcatheter Mitral Valve Repair — Joe Cleveland, M.D.
VIDEO: Transcatheter Mitral Valve Technology, Anatomical Challenges — Interview with Juan Granada, M.D.
This video, provided by Abbott/St. Jude Medical, demonstrates how the Nanostim leadless pacemaker is delivered via catheter. This eliminates the need for open surgical procedures. It is anchored into the myocardium at apex of the right ventricle. Watch the VIDEO “Current State of Leadless Pacemaker Technology,” an interview with Vivek Reddy, M.D.
American Society of Echocardiography (ASE) President Benjamin Byrd III, M.D., FASE, explains some of the recent trends and issues facing cardiac ultrasound. These trends include reimbursement issues, the rapid expansion of point-of-care ultrasound and the critical role played by the new sub-specialty of interventional ultrasound.
DAIC Editor Dave Fornell highlights some of the biggest trends and most innovative technology discussed during the American Society of Echocardiology (ASE) 2013 annual meeting.
Saint Luke's Mid America Heart Institute has a clear and immediate picture of their cardiovascular performance metrics with the help of Lumed's HealthView Financial Dashboard.
Watch the VIDEO “Lumedx Cardiovascular Performance Program: A New Approach to Managing Quality and Cost.” For more information, visit www.lumedx.com
Agfa Healthcare introduced new functionality and workflow improvements for its completely revised cardiovascular information system (CVIS), introduced at the American College of Cardiology 2013 meeting. The CV12 system offers new solutions for echocardiography, nuclear perfusion imaging, cath lab reporting and ECG management and reporting. For more information, visit www.agfahealthcare.com
SunTech demonstrated its new Tango M2 cardiac stress test automated blood pressure monitoring system at the American College of Cardiology (ACC) 2013. The system eliminates the need to manually take blood pressure readings during a stress test, which can sometimes be difficult because of patient motion. It also allows clinicians to focus on the patient and the test instead of worrying about periodic blood pressure measurements. For more information, visit www.SunTechMed.com/TM2Info
McKesson highlighted enhancements to its cardiovascular information system (CVIS) version 13. The system offers new modules for electrophysiology, inventory control and aids interoperability for better change capture and data mining. For more information, visit www.allaboutCVIS.com
Ajay Kirtane, M.D., SD, chief academic officer at Columbia University Medical Center/New York Presbyterian Hospital, explains the key highlights regarding interventional cardiology at the American College of Cardiology (ACC) 2013. These included data on the use of cangrelor vs. clopidogrel during cath lab procedures, first U.S. reports on using the smaller Sapient XT transcatheter aortic valve, and the safety of using shorter duration dual-antiplatelet therapy with drug-eluting stents.
The American College of Cardiology (ACC) 2013 Scientific Session Committee Chairman Miguel Quinones, M.D., explains some of the key highlights from this year's meeting. Highlights included the impact of niacin on lowering cholesterol, new data on transcatheter aortic valve repair, and how mummies show atherosclerosis is not a modern disease.
DAIC Editor Dave Fornell explains his choices for the most innovative new technology on the expo floor at the American College of Cardiology (ACC) 2013. These include new angiography systems, dose monitoring software and technology integrations, an iPhone ECG monitoring device, ultrasound-aided CRT lead optimization, and new radiation protection aprons that are up to 50 percent lighter.
The Iowa Heart Center created a telecardiology program that connects cardiologists in Des Moines with satellite facilities in rural towns around the state. With help from Esaote, patients can have their echo exams performed on a compact ultrasound system and delivered to Des Moines for review by experts. Iowa Heart will detail its program during sessions at ACC.2013, March 9-11, in San Francisco.
This short cine loop shows a 3-D/4-D transesophegeal echo (TEE) view of a transcatheter Amplatzer closure device used to seal an atrial septal defect (ASD) and the operation of a surgically implanted St. Jude Medical mechanical mitral valve. This type of complex ASD transcatheter repair is much easier to perform under real-time 3-D TEE guidance. This image was provided by GE Healthcare's Vivid E9 Breakthrough 2012 (BT12), which includes a 4-D transducer for TEE.
At RSNA 2012, Hitachi featured its Echelon Oval 1.5T MRI system, which features the widest bore on the market at 74 cm, a wide table and the ability to perform non-contrast MR angiography exams. Hitachi also highlighted new features for its Scenaria CT system, which is upgradeable to a 128-slice system, offers new, faster iterative reconstruction software and cardiac imaging packages.
DAIC Editor Dave Fornell highlights the latest advancements that will impact cardiovascular imaging from the 2012 Radiological Society of North America (RSNA) meeting. RSNA is the largest medical imaging show in the world and most advancements are shown here first.
Imaging Technology News experts discuss the trends and latest technology they saw on the show floor and in sessions at RSNA 2012. Their discussions include some of the most innovative new devices and software to solve issues facing radiology today.
One-year results from the ADAPT-DES Trial were presented during TCT 2012. It examined patient hyporesponsiveness to clopidogrel and aspirin in a large-scale, prospective, multicenter study.
Mercy Hospital in Chicago has developed a successful hybrid cath lab program where various specialties work together for the best, minimally invasive patient outcomes. Beyond the coronaries, this cath lab specializes in endovascular aortic stent grafting, peripheral vascular disease, embolization procedures and transcatheter heart valve replacements. Read the related article "Most Innovative Heart Centers: Chicago’s Mercy Hospital." Watch the related Mercy VIDEO "Mercy Hospital Develops Effective, Collaborative Interventional Program."
Mercy Hospital in Chicago developed an interventional program around its hybrid cath labs, fostering collaboration between interventional cardiologists, vascular surgeons and interventional radiologists. This collaboration has helped the hospital improve care and keep costs low in order to serve the Chicago South Side's low-income population. Read the article "Most Innovative Heart Centers: Chicago’s Mercy Hospital." There is also a related VIDEO about Mercy, "Developing a Hybrid Cath Lab Program."
Results from the POSEIDON Trial were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2012. Data showed a positive strategy to prevent contrast-induced nephropathy (CIN) in patients with renal impairment undergoing interventional catheterization procedures. CIN is also referred to as acute kidney injury (AKI). The data is presented in a press conference by Sonjot Brar, M.D., MPH, Kaiser Permanente.
Related CIN Content:
VIDEO: How to Avoid Acute Kidney Injury in the Cath Lab — Interview with Hitinder Gurm, M.D.
VIDEO: Strategies to Avoid Acute Kidney Injury Caused by Cath Lab Contrast — Interview with Roxana Mehran, M.D.
The PC Trial data presented at TCT 2012 looked at transcather PFO closure vs. medical therapy in preventing cryptogenic strokes.
The results of the FAME II Trial were presented at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) meeting. The study showed the cost effectveness of fractional-flow reserve (FFR) therapy vs. standard medical therapy.
Positive results from the RESPECT Trial of transcatheter patent foramen ovale (PFO) closure vs. standard medical therapy were presented by John Carroll, M.D., University of Colorado Hospital, at the Transcatheter Cardiovascular Therapeutics (TCT) 2012 meeting.
Read the article on the trial results — "PFO Closure May Improve Outcomes Over Medical Therapy in Cryptogenic Stroke."
Diagnostic and Interventional Cardiology Editor Dave Fornell shares his choices of the latest advances in cardiac ultrasound from the show floor of the American Society of Echocardiography (ASE) 2012. With the increasing use of more complex interventional procedures, transesophageal echo (TEE) and intracardiac echo (ICE) are being used for guidance to reduce fluoroscopic radiation dose.
This video, provided by Crux Biomedical, demonstrates the implantation of the FDA-cleared Crux VCF inferior vena cava filter (VCF) with bi-directional retrieval. It is designed to trap blood clots that can lead to potentially fatal pulmonary embolisms among patients at risk. The Crux VCF is the first designed to facilitate bi-directional retrieval through either the femoral or jugular veins, a key consideration when access to one or the other vein is limited. The helical shape was designed to self-center and to conform more closely to the shape of the vena cava, as well as to reduce bends and stress that can compromise filter integrity. Read the article "Large-Scale Inferior Vena Cava Filters Study Examines Safety and Effectiveness of These Devices."